Cargando…
SGLT1: A Potential Drug Target for Cardiovascular Disease
SGLT1 and SGLT2 are the two main members of the sodium-glucose cotransporters (SGLTs), which are mainly responsible for glucose reabsorption in the body. In recent years, many large clinical trials have shown that SGLT2 inhibitors have cardiovascular protection for diabetic and non-diabetic patients...
Autores principales: | Zhao, Mengnan, Li, Na, Zhou, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332373/ https://www.ncbi.nlm.nih.gov/pubmed/37435096 http://dx.doi.org/10.2147/DDDT.S418321 |
Ejemplares similares
-
Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023) -
Potential Drug Targets for Ceramide Metabolism in Cardiovascular Disease
por: Guo, Jiaying, et al.
Publicado: (2022) -
SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
por: Li, Na, et al.
Publicado: (2020) -
SGLT2 Inhibitors as Potential Anticancer Agents
por: Basak, Debasish, et al.
Publicado: (2023) -
SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)